1.29%
9.25%
1.22%
-5.95%
2.56%
0.07%
49.02%
AI Spotlight on STE
Company Description
STERIS plc provides infection prevention and other procedural products and services worldwide.It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental.The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services.The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities.The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors.
This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services.The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite.The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers.
The company was founded in 1985 and is based in Dublin, Ireland.
Market Data
| Last Price | 224.56 |
| Change Percentage | 1.29% |
| Open | 219.79 |
| Previous Close | 221.7 |
| Market Cap ( Millions) | 22166 |
| Volume | 204835 |
| Year High | 248.24 |
| Year Low | 197.82 |
| M A 50 | 212.55 |
| M A 200 | 222.88 |
Financial Ratios
| FCF Yield | 3.07% |
| Dividend Yield | 0.97% |
| ROE | 6.78% |
| Debt / Equity | 36.40% |
| Net Debt / EBIDTA | 165.69% |
| Price To Book | 3.37 |
| Price Earnings Ratio | 51.06 |
| Price To FCF | 32.59 |
| Price To sales | 4.09 |
| EV / EBITDA | 18.14 |
News
- Jan -28 - STERIS Declares Dividend of $0.57 per share
- Jan -22 - STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025
- Jan -21 - STERIS Announces Outcome of Ethylene Oxide Trial
- Dec -17 - Reasons to Retain STE Stock in Your Portfolio Now
- Nov -27 - New Alliances to Support STERIS Stock Despite Macro Issues
- Nov -18 - Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
- Nov -11 - Why Steris (STE) International Revenue Trends Deserve Your Attention
- Nov -07 - STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
- Nov -07 - Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics
- Nov -06 - Steris (STE) Surpasses Q2 Earnings Estimates
- Nov -06 - Steris beats quarterly estimates on continued demand for medical procedures
- Nov -06 - STERIS Announces Financial Results for Fiscal 2025 Second Quarter
- Nov -01 - Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Oct -30 - STERIS Declares Dividend of $0.57 per share
- Oct -30 - Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
- Oct -23 - STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024
- Oct -21 - STE Gears Up for Q2 Earnings: Here's What You Need to Know
- Sep -04 - Reasons to Retain STERIS Stock in Your Portfolio for Now
- Aug -29 - 15 Upcoming Dividend Increases Including A King
- Aug -26 - STERIS to Present at the Morgan Stanley Healthcare Conference
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Healthcare
Expected Growth : 5.5 %
What the company do ?
STERIS plc's Healthcare segment provides infection prevention and procedural product solutions to healthcare facilities, including sterilizers, washers, and other medical equipment.
Why we expect these perspectives ?
STERIS plc's 5.5% growth in Healthcare is driven by increasing demand for sterilization and disinfection solutions, fueled by the COVID-19 pandemic and growing concerns over hospital-acquired infections. Additionally, the company's strategic acquisitions and investments in innovative technologies, such as robotic sterilization systems, are expanding its market share and driving revenue growth.
Segment n°2 -> Applied Sterilization Technologies
Expected Growth : 5.8 %
What the company do ?
Applied Sterilization Technologies from STERIS plc provides low-temperature sterilization solutions for medical devices, using technologies like ethylene oxide and nitrogen dioxide.
Why we expect these perspectives ?
STERIS plc's Applied Sterilization Technologies segment growth of 5.8% is driven by increasing demand for sterilization services in the healthcare industry, expansion into emerging markets, and strategic acquisitions. Additionally, the growing need for infection prevention and control, coupled with advancements in sterilization technologies, contribute to the segment's growth.
Segment n°3 -> Life Sciences
Expected Growth : 6.2 %
What the company do ?
Life Sciences from STERIS plc provides contamination control and sterilization solutions for pharmaceutical, biotechnology, and medical device industries.
Why we expect these perspectives ?
STERIS plc's Life Sciences segment growth of 6.2% is driven by increasing demand for sterilization and lab equipment, expansion in biotech and pharmaceutical industries, and growing need for contamination control solutions. Additionally, strategic acquisitions and investments in R&D have enhanced the company's product offerings, contributing to the segment's growth.
Segment n°4 -> Dental
Expected Growth : 5.2 %
What the company do ?
STERIS plc's Dental segment provides infection prevention and surgical solutions to dental clinics and practices, ensuring a safe and clean environment for patients and staff.
Why we expect these perspectives ?
STERIS plc's Dental segment growth of 5.2% is driven by increasing demand for infection prevention and control solutions, expansion in emerging markets, and strategic acquisitions. Additionally, the growing need for dental practices to maintain compliance with regulatory standards and the rising importance of patient safety are contributing to the segment's growth.
Steris Plc Products
| Product Range | What is it ? |
|---|---|
| Sterilization Systems | STERIS plc provides a range of sterilization systems, including steam sterilizers, ethylene oxide sterilizers, and hydrogen peroxide gas plasma sterilizers, designed to meet the specific needs of hospitals, pharmaceutical companies, and research institutions. |
| Infection Prevention Technologies | STERIS plc offers a range of infection prevention technologies, including UV light disinfection systems, automated room disinfection systems, and surface disinfection systems, designed to reduce the risk of healthcare-associated infections. |
| Endoscopy Reprocessing | STERIS plc provides a range of endoscopy reprocessing systems, including automated endoscope reprocessors and endoscope drying cabinets, designed to ensure the safe and effective reprocessing of endoscopes. |
| Pharmaceutical Processing Equipment | STERIS plc offers a range of pharmaceutical processing equipment, including bioreactors, fermentation systems, and purification systems, designed to support the development and manufacturing of pharmaceuticals and biologics. |
| Laboratory and Medical Equipment | STERIS plc provides a range of laboratory and medical equipment, including autoclaves, centrifuges, and microscopes, designed to support research, development, and patient care. |
| Service and Maintenance | STERIS plc offers a range of service and maintenance programs, including equipment maintenance, validation, and calibration, designed to ensure the optimal performance and compliance of equipment. |
STERIS plc's Porter Forces
Threat Of Substitutes
STERIS plc operates in a niche market with high barriers to entry, reducing the threat of substitutes. However, the company's dependence on a few large customers increases the risk of substitution.
Bargaining Power Of Customers
STERIS plc's customers, primarily hospitals and healthcare facilities, have significant bargaining power due to their large purchasing volumes and ability to negotiate prices.
Bargaining Power Of Suppliers
STERIS plc's suppliers, primarily manufacturers of medical equipment and consumables, have limited bargaining power due to the company's large purchasing volumes and diversified supply chain.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the medical equipment and consumables market, including regulatory hurdles and significant capital requirements.
Intensity Of Rivalry
The medical equipment and consumables market is moderately competitive, with a few large players competing for market share. However, STERIS plc's strong brand reputation and diversified product portfolio help to mitigate the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 33.07% |
| Debt Cost | 3.95% |
| Equity Weight | 66.93% |
| Equity Cost | 7.95% |
| WACC | 6.63% |
| Leverage | 49.41% |
STERIS plc : Quality Control
STERIS plc passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHIA.AS | Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The … |
| BSX | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company … |
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| DRW3.DE | Drägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, … |
| SOON.SW | Sonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Sanofi
A-Score
1-Year Total Return ->
🥈
Drägerwerk
A-Score
1-Year Total Return ->
🥉
Boston Scientific
A-Score
1-Year Total Return ->
4
Sonova
A-Score
1-Year Total Return ->
5
STERIS
A-Score
1-Year Total Return ->
6
